本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第三次临时股东大会 召开的日期时间：2024 年 12 月 23 日 14 点 50 分 召开地点：江西省南昌市高新开发区火炬大街 788 号公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 证券代码：600750 证券简称：江中药业 公告编号：2024-057 江中药业股份有限公司 关于召开 2024 年第三次临时股东大会的通知 网络投票起止时间：自 2024 年 12 月 23 日 至 2024 年 12 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、 ...

证券代码：600750 证券简称：江中药业 公告编号：2024-053 江中药业股份有限公司 关于 2021 年限制性股票激励计划首次授予部分 第二个解除限售期解锁暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 1,578,408 股。 本次股票上市流通总数为 1,578,408 股。 本次股票上市流通日期为 2024 年 12 月 2 日。 江中药业股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开第九 届董事会第二十四次会议和第九届监事会第十八次会议，审议通过了《关于公司 2021 年限制性股票激励计划首次授予部分第二个解锁期解锁条件成就的议案》。根 据《2021 年限制性股票激励计划（2022 年 11 月修订稿）》（以下简称"激励计划"） 的有关规定和公司 2021 年第二次临时股东大会的授权，公司董事会认为公司激励 计划规定的首次授予部分限制性股票第二个解除限售期解除限售条件已经成就。 本次符合解除 ...

Investment Rating - The report maintains a rating of "Accumulate" for Jiangzhong Pharmaceutical [1] Core Views - Jiangzhong Pharmaceutical's Q3 2024 results show stable profit growth, but the health business needs recovery. The company achieved a revenue of 2.972 billion yuan in the first three quarters of 2024, a year-on-year decrease of 8.19%, while the net profit attributable to shareholders was 634 million yuan, an increase of 7.09% year-on-year [2][3] Financial Performance Summary - Revenue for 2022 was 3.885 billion yuan, with a growth rate of 35.2%. In 2023, revenue is projected at 4.390 billion yuan, reflecting a growth rate of 13.0%. However, a decline of 2.6% is expected in 2024, with revenues estimated at 4.275 billion yuan. The company anticipates a recovery in 2025 and 2026, with revenues of 4.756 billion yuan and 5.425 billion yuan, respectively, representing growth rates of 11.3% and 14.1% [1][5] - The net profit attributable to shareholders for 2022 was 598 million yuan, with a growth rate of 18.3%. The net profit for 2023 is expected to be 708 million yuan, with a growth rate of 18.4%. The company forecasts net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 12.3%, 13.4%, and 15.1% [1][5] - The overall gross margin for Q3 2024 decreased by 2.97 percentage points to 63.94%. The gross margins for OTC, prescription drugs, and health products were 72.32%, 43.29%, and 23.62%, respectively, with year-on-year changes of +0.53, -15.39, and -25.32 percentage points [3] Business Segment Performance - The OTC segment generated revenue of 2.335 billion yuan, a year-on-year increase of 2.78%, accounting for 78.57% of total revenue, which is an increase of 6.25 percentage points. The prescription drug segment saw revenue of 365 million yuan, a decline of 25.10%, primarily due to changes in product structure from unsuccessful bids in centralized procurement. The health business generated revenue of 249 million yuan, a significant decrease of 45.73% due to slower expansion and product adjustments [2][3] Future Outlook - The report projects revenues of 4.275 billion yuan, 4.756 billion yuan, and 5.425 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan. The expected P/E ratios for these years are 17.8, 15.7, and 13.7, respectively [3][5]

24年的三季报,我们也非常高兴看到公司在业绩上取得了持续稳健的表现,努力能力也同时取得了稳固的提升,公司围绕着做强OPC,发展大健康,布局处方要三大 今天我们很荣幸的邀请到了交通药业的总经理萧文斌先生董益田永信女士与我们一同分享公司的近期经营情况接下来我们把时间交给公司管理层介绍前三季度的经营情况和财务情况随后我们将开放线上问答下面有请公司管理层谢谢 各位投资朋友大家好我是江峰商业总经理陈永静感谢各位参加江峰商业2024年第三季度业余交易会今天和我一起出席会议的爱用人总经理萧文斌总那么今天的业务会议将先由我为各位简单介绍公司第三季度的情况随后由萧总和我共同回复各位投资者的提问 2024年前三季度公司实现营收29.8亿从并下降8个点实现规模经验论6.34亿元从并增长7个点那跟场景类型看呢OPC业务前三季度实现了营收23.35亿从并增长2.8个点毛利率同时增加1.35个百分点整体开朗稳定 粗方向业务前三季度实现营收3.05亿,同比下降100%。毛利率曾经减少约15%。主要原因是子公司海思资料部分高毛利产品无以及彩控标,引起产品和产品的收入结构的变化,本土收入规模和毛利率水平出现下降。 战略上业务前三季度实现营收2 ...

江中药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：600750 证券简称：江中药业 公告编号：2024-051 江中药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原由 江中药业股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开第九 届董事会第二十四次会议及第九届监事会第十八次会议，审议通过了《关于回购 注销部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的议 案》。鉴于 2 名激励对象辞职、2 名激励对象到龄退休及 4 名激励对象年度个人 绩效考核不符合第二个解除限售期全部解锁要求，根据《江中药业股份有限公司 2021 年限制性股票激励计划（2022 年 11 月修订稿）》《上市公司股权激励管理办 法》等相关规定，公司对上述 8 名激励对象已获授但尚未解除限售的限制性股票 共计 111,133 股进行回购注销（具体内容详见公司同日披露的《关于 2021 年限 制性股票激励计划回购注销部分限制性股票及调整回购价格的公告》（公告编号： 2024-050） ...

表决情况：9 票同意，0 票反对，0 票弃权，通过本议案。 董事会认为，《江中药业 2024 年第三季度报告》真实反映了公司 2024 年第 三季度的财务状况和经营成果，编制程序符合相关法律法规、中国证券监督管理 委员会和上海证券交易所的相关规定，报告内容真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 公司审计委员会 2024 年第六次会议已事前审议通过本议案，并同意提交董 事会审议。 具体情况详见公司同日于上海证券交易所网站（www.sse.com.cn）披露的《江 中药业 2024 年第三季度报告》。 证券代码：600750 证券简称：江中药业 公告编号：2024-047 江中药业股份有限公司 第九届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"或"江中药业"）第九届董事会 第二十四次会议于 2024 年 10 月 24 日下午 2:00 在公司会议室以现场结合视频方 式召开，会议通知于 2024 年 10 月 18 日以书面形式发出， ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥799,352,122.10, a decrease of 8.64% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥145,587,454.62, representing a slight increase of 2.15% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥144,317,854.68, showing a decrease of 0.64% compared to the previous year[3]. - Total operating revenue for the first nine months of 2024 was CNY 2,971,879,125.96, a decrease of 8.2% compared to CNY 3,236,916,800.27 in the same period of 2023[23]. - Total operating costs for the same period were CNY 2,215,871,404.32, down 13.1% from CNY 2,549,157,745.08 year-over-year[23]. - Operating profit increased to CNY 806,852,228.86, compared to CNY 731,516,551.39 in the previous year, reflecting a growth of 10.3%[23]. - The total profit for Q3 2024 was CNY 807,563,569.73, an increase from CNY 738,065,247.24 in Q3 2023, representing a growth of approximately 9.1%[24]. - The net profit attributable to shareholders of the parent company reached CNY 634,340,897.79, up from CNY 592,326,126.97 in the same period last year, reflecting an increase of about 7.1%[24]. - Basic and diluted earnings per share for Q3 2024 were both CNY 1.01, compared to CNY 0.94 in Q3 2023, indicating a growth of approximately 7.4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥6,126,752,091.97, a decrease of 0.03% from the end of the previous year[4]. - Total assets amounted to CNY 6,126,752,091.97, slightly down from CNY 6,128,543,353.58 at the end of the previous quarter[21]. - Total liabilities increased to CNY 1,894,757,777.87, up from CNY 1,653,436,913.49, indicating a rise of 14.6%[21]. - The company's equity attributable to shareholders decreased to CNY 3,717,863,952.26 from CNY 3,831,520,111.84, a decline of 2.9%[21]. - The company's cash and cash equivalents as of September 30, 2024, amount to ¥907,975,361.03, down from ¥1,332,928,513.42 at the end of 2023[19]. - The total assets as of September 30, 2024, amount to ¥2,028,393,575.15, down from ¥2,397,129,852.82 at the end of 2023[19]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥442,960,892.68, down 22.79% compared to the previous year[3]. - Cash flow from operating activities for the first nine months of 2024 was CNY 442,960,892.68, down from CNY 573,736,148.12 in the same period of 2023, a decrease of about 22.8%[25]. - Cash inflow from operating activities totaled CNY 3,020,914,317.85, compared to CNY 3,410,995,656.64 in the previous year, showing a decline of approximately 11.4%[25]. - Cash outflow from operating activities was CNY 2,577,953,425.17, down from CNY 2,837,259,508.52 in the same period last year, a decrease of about 9.1%[25]. - The net cash flow from investing activities was -CNY 79,610,953.21, an improvement from -CNY 514,881,214.49 in the same period of 2023[27]. - The total cash and cash equivalents at the end of Q3 2024 were CNY 557,405,366.27, compared to CNY 184,567,762.31 at the end of Q3 2023, indicating a significant increase[27]. - The company reported a decrease in cash received from sales of goods and services, totaling CNY 2,892,277,770.85, down from CNY 3,301,957,866.25 in the previous year, a decline of approximately 12.4%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,276[13]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group, holds 271,071,486 shares, accounting for 43.09% of total shares[13]. - The company has no significant changes in the top ten shareholders or their participation in margin financing and securities lending[15]. Industry Performance - The pharmaceutical industry segment generated revenue of ¥2,940,670,027.53, down 8.35% year-on-year[8]. - Revenue from prescription drugs decreased by 25.10%, while non-prescription drugs saw a revenue increase of 2.78%[8]. - The revenue from the South China region increased by 1.88%, while the North and East China regions saw declines of 11.76% and 10.18%, respectively[9]. Investments and Acquisitions - The company acquired 100% equity of Jiangxi Jiangzhong Changrun Pharmaceutical Co., Ltd. and Jiangxi Jiangzhong Bencao Health Technology Co., Ltd. in November 2023[4]. - The company has entrusted a total of ¥180,000,000 in wealth management products, with expected annualized returns of 3.68% and 3.05% for different products[16]. - The company has a long-term equity investment valued at ¥30,935,089.44, slightly down from ¥31,295,176.87 in the previous period[19]. - The company has a non-recoverable loan of ¥6,750,000 from Changrong Automobile, with legal actions ongoing to recover the amount[18]. Research and Development - Research and development expenses rose to CNY 77,862,125.99, an increase of 9.0% from CNY 70,843,909.82 in the same period last year[23]. Future Outlook - Future outlook includes potential market expansion and new product development initiatives aimed at enhancing revenue streams[22]. - The company has not indicated any new product launches or significant market expansion strategies in the current report[28].

国浩律师（上海）事务所 关 于 法律意见书 上海市北京西路 968 号嘉地中心 27 楼接待中心 邮编：200041 27/F, Garden Square, 968 West Beijing Road, Shanghai 200041, China T. +86 21 5234 1668 F. +86 21 5234 1670 E. grandallsh@grandall.com.cn W. www.grandall.com.cn 2024 年 10 月 | 释 义 | | | 2 | | --- | --- | --- | --- | | 第一节 | | 律师声明事项 | 5 | | 第二节 | 正文 | | 6 | | | | 一、本次回购注销的批准与授权 | 6 | | | | 二、本次回购注销的主要内容 | 10 | | 三、结论意见 | | | 13 | 国浩律师（上海）事务所 法律意见书 释 义 以下词语如无特殊说明，在本文中具有如下含义： 江中药业股份有限公司 2021 年限制性股票激励计划 回购注销部分限制性股票事宜 的 | 江中药业、本公司、公司 | 指 | 江中药业股份有限公司 | | ...

国浩律师（上海）事务所 关 于 江中药业股份有限公司 2021 年限制性股票激励计划首次授予部分 第二个解锁期解锁条件成就 的 法律意见书 | 释 义 | | | 2 | | --- | --- | --- | --- | | 第一节 | 律师声明事项 | | 4 | | 第二节 | 正文 | | 5 | | | 一、本次解除限售的批准与授权 | | 5 | | | 二、本次解除限售条件成就情况 | | 9 | | 三、结论意见 | | 11 | | 国浩律师（上海）事务所 法律意见书 释 义 以下词语如无特殊说明，在本文中具有如下含义： | 江中药业、本公司、公司 | 指 | 江中药业股份有限公司 | | --- | --- | --- | | 本次激励计划、本激励计 | 指 | 江中药业股份有限公司 年限制性股票激励计划 2021 | | 划、激励计划 | | | | 本次解除限售 | 指 | 江中药业股份有限公司 年限制性股票激励计划首 2021 | | | | 次授予部分第二个解除限售期解除限售条件成就事宜 | | 《2021 年限制性股票激励 | 指 | 《江中药业股份有限公司 2021 年限制性股 ...